GRCE - Grace Therapeutics • Financials

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
03/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2024	0	-13	-	0%	L	62	L	-23	-	-13	-0	7	-13	0	0	-	-
03/2025	0	-17	-	0%	L	67	L	-22	-	-16	0	14	-16	-1	0	-	-
03/2026	0	-11	-	0%	L	64	L	-17	-	-10	0	4	-10	-0	0	-	-

To see all financials—including updated, you must be Premium.